Sugi Predict

Sugi Predict / Compounds / SCHEMBL30356

SCHEMBL30356

SCHEMBL30356

O=[N+]([O-])c1ccc2ccn(C3O[C@H](CO)[C@@H](O)[C@H]3O)c2c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 2/20 0.48
▸ THRB P10828 1/20 0.48
▸ MTOR P42345 1/20 0.48
▸ MDM2 Q00987 1/20 0.48
▸ NCOA1 Q15788 1/20 0.48
▸ NCOA3 Q9Y6Q9 1/20 0.48
▸ SLC29A1 Q99808 10/20 0.48
▸ SLC28A1 O00337 1/20 0.47
▸ SLC28A2 O43868 1/20 0.47
▸ SLC28A3 Q9HAS3 1/20 0.47
▸ ADORA3 P0DMS8 1/20 0.47
▸ CYP1A2 P05177 1/20 0.46
▸ NFKB1 P19838 1/20 0.46
▸ THPO P40225 1/20 0.46
▸ ALDH1A1 P00352 1/20 0.46
▸ PMP22 Q01453 1/20 0.46
▸ RAB9A P51151 1/20 0.46
▸ CYP3A4 P08684 1/20 0.46
▸ PKM P14618 1/20 0.46
▸ HPGD P15428 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1372596 1.00 LMNA (0.48) LMNATHRBMTORMDM2NCOA1
SCHEMBL14534827 0.92 LMNA (0.49) LMNATHRBMTORMDM2NCOA1
SCHEMBL14084325 0.92 LMNA (0.49) LMNATHRBMTORMDM2NCOA1
SCHEMBL1062447 0.92 LMNA (0.49) LMNATHRBMTORMDM2NCOA1
SCHEMBL29703 0.92 LMNA (0.49) LMNATHRBMTORMDM2NCOA1
SCHEMBL29446054 0.92 LMNA (0.49) LMNATHRBMTORMDM2NCOA1
SCHEMBL11934657 0.83 SLC29A1 (0.42) LMNATHRBMTORMDM2NCOA1
SCHEMBL11934656 0.83 SLC29A1 (0.42) LMNATHRBMTORMDM2NCOA1
SCHEMBL650683 0.79 CYP1A2 (0.42) SLC29A1ADORA3CYP1A2NFKB1THPO
SCHEMBL1777532 0.78 LMNA (0.49) LMNATHRBMTORMDM2NCOA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150258130-A1 NICKED OR GAPPED NUCLEIC ACID MOLECULES AND USES THEREOF MARINA BIOTECH, INC. (US) 2015-09-17 — — US disclosed
US-20150259686-A1 NICKED OR GAPPED NUCLEIC ACID MOLECULES AND USES THEREOF MARINA BIOTECH, INC. (US) 2015-09-17 — — US disclosed
US-9074205-B2 Nicked or gapped nucleic acid molecules and uses thereof MARINA BIOTECH, INC. (US) 2015-07-07 — — US disclosed
WO-2014094645-A1 RNA INTERFERENCE PREPARATION FOR CURING HBV 厦门成坤生物技术有限公司 (CN) 2014-06-26 — — WO disclosed
EP-2609198-A1 SINGLE-STRANDED RNAi AGENTS CONTAINING AN INTERNAL, NON-NUCLEIC ACID SPACER Merck Sharp & Dohme Corp. (US) 2013-07-03 — — EP disclosed
WO-2013036868-A1 SYNTHESIS AND USES OF NUCLEIC ACID COMPOUNDS WITH CONFORMATIONALLY RESTRICTED MONOMERS MARINA BIOTECH INC. (US) 2013-03-14 — — WO disclosed
EP-2563922-A1 NUCLEIC ACID COMPOUNDS WITH CONFORMATIONALLY RESTRICTED MONOMERS AND USES THEREOF Marina Biotech, Inc. (US) 2013-03-06 — — EP disclosed
US-20130011922-A1 NUCLEIC ACID COMPOUNDS FOR INHIBITING GENE EXPRESSION AND USES THEREOF F/K/A MDRNA, INC. (US) 2013-01-10 — — US disclosed
WO-2012027206-A1 SINGLE-STRANDED RNAi AGENTS CONTAINING AN INTERNAL, NON-NUCLEIC ACID SPACER MERCK SHARP & DOHME CORP. (US) 2012-03-01 — — WO disclosed
WO-2011139710-A1 NUCLEIC ACID COMPOUNDS WITH CONFORMATIONALLY RESTRICTED MONOMERS AND USES THEREOF MARINA BIOTECH, INC. (US) 2011-11-10 — — WO disclosed
WO-2008109353-A1 NUCLEIC ACID COMPOUNDS FOR INHIBITING MAP2K GENE EXPRESSION AND USES THEREOF MDRNA, INC. (US) 2008-09-12 — — WO disclosed
WO-2008109520-A2 NUCLEIC ACID COMPOUNDS FOR INHIBITING CXC GENE EXPRESSION AND USES THEREOF MDRNA, INC. (US) 2008-09-12 — — WO disclosed
WO-2008109487-A2 NUCLEIC ACID COMPOUNDS FOR INHIBITING MME GENE EXPRESSION AND USES THEREOF MDRNA, INC. (US) 2008-09-12 — — WO disclosed
WO-2008109474-A1 NUCLEIC ACID COMPOUNDS FOR INHIBITING FGF2 GENE EXPRESSION AND USES THEREOF MDRNA, INC. (US) 2008-09-12 — — WO disclosed
WO-2008109475-A1 NUCLEIC ACID COMPOUNDS FOR INHIBITING SIRT2 GENE EXPRESSION AND USES THEREOF MDRNA, INC. (US) 2008-09-12 — — WO disclosed
WO-2008109473-A1 NUCLEIC ACID COMPOUNDS FOR INHIBITING ABCB1 GENE EXPRESSION AND USES THEREOF MDRNA, INC. (US) 2008-09-12 — — WO disclosed
WO-2008109449-A1 NUCLEIC ACID COMPOUNDS FOR INHIBITING BCL2 GENE EXPRESSION AND USES THEREOF MDRNA INC. (US) 2008-09-12 — — WO disclosed
WO-2008109455-A1 NUCLEIC ACID COMPOUNDS FOR INHIBITING MAPK3 GENE EXPRESSION AND USES THEREOF NASTECH PHARMACEUTICAL COMPANY INC. (US) 2008-09-12 — — WO disclosed
WO-2008049078-A1 NICKED OR GAPPED NUCLEIC ACID MOLECULES AND USES THEREOF NASTECH PHARMACEUTICAL COMPANY INC. (US) 2008-04-24 — — WO disclosed
WO-2008022046-A2 DICER SUBSTRATE RNA PEPTIDE CONJUGATES AND METHODS FOR RNA THERAPEUTICS NASTECH PHARMACEUTICAL COMPANY INC. (US) 2008-02-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130011922-A1 NUCLEIC ACID COMPOUNDS FOR INHIBITING GENE EXPRESSION AND USES THEREOF POLRMT, RNMT, SNRPE LMNA 430/4885THRB 2067/4885MTOR 4221/4885
US-20150258130-A1 NICKED OR GAPPED NUCLEIC ACID MOLECULES AND USES THEREOF RNMT, POLRMT, SNRPE LMNA 386/4885THRB 2433/4885MTOR 4236/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.